The market has been high on Lipocine Inc (LPCN) stock recently. LPCN gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObservers Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

Lipocine Inc (LPCN) stock is higher by 6.88% while the S&P 500 is lower by -0.33% as of 1:30 PM on Monday, Dec 7. LPCN is higher by $0.11 from the previous closing price of $1.54 on volume of 1,510,095 shares. Over the past year the S&P 500 has gained 17.57% while LPCN is higher by 312.50%. LPCN lost -$0.44 per share in the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Lipocine Inc click here.

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148 and LPCN 1107.

Click Here to get the full Stock Score Report on Lipocine Inc (LPCN) Stock.

Here is the original post:
Is Lipocine Inc (LPCN) a Stock to Watch This Week? - InvestorsObserver